Education
About Us
Working with TipRanks
Follow Us
Vicore Pharma Holding AB (DE:6Y4)
FRANKFURT:6Y4
6Y4 Stock Chart & Stats
€0.92
€0.08(9.48%)
At close: 4:00 PM EST
€0.92
€0.08(9.48%)
Day’s Range― - ―
52-Week Range€0.52 - €1.18
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€283.16M
Enterprise Value€2.03B
Total Cash (Recent Filing)€936.98M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Feb 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding281,525,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.69
Price to Sales (P/S)17.41
P/FCF Ratio-11.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNear-zero debt and a materially larger equity base provide durable financial flexibility for multi-year clinical programs. Reduced leverage lowers refinancing and interest risk, enabling the company to fund trials or partnerships without immediate solvency pressure, a long-term stability factor.
Revenue InflectionThe 2024 revenue inflection demonstrates initial commercial or collaboration traction, reducing the binary reliance solely on future trial outcomes. Sustained revenue or recurring collaboration income would support R&D funding and improve the company's ability to invest in longer-term development plans.
Focused R&D PlatformA concentrated AT2R research platform and a clear lead candidate create deep domain expertise and a differentiated pipeline. Specialization in severe lung diseases builds a defensible scientific niche, improving chances for meaningful clinical progress and potential premium partnerships over the medium term.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow indicates the company consumes significant cash to fund development. Over months to a few years this necessitates external financing, which can dilute shareholders or constrain timing of trials and launches, limiting strategic optionality.
Ongoing Net Losses And Negative MarginsLarge, sustained losses and negative margins reflect that operations do not produce positive returns and that spending remains heavy. This weakens internal capital generation, increases reliance on external funding, and makes profitability recovery uncertain absent successful clinical/ commercial outcomes.
Clinical-stage Execution RiskAs a clinical-stage biopharma with no established commercial product, the company faces structural binary risks from trial outcomes and regulatory timing. Long development horizons and high failure rates mean program setbacks can materially impair long-term revenue prospects and funding needs.
Vicore Pharma Holding AB News
6Y4 FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was €0.52 and its highest was €1.18 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is €283.16M.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Feb 27, 2026 which is in 10 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on Nov 05, 2025. The company reported -€0.048 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.048.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Overvalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.04.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -€0.048 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.185%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6Y4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---